


**Supplemental Materials**

**Supplemental Table I. Effects of *APOC3* R19X Mutation on Kinetic Parameters for plasma apoCIII and apoCII Metabolism.**


		<b>CC (±SD)</b>	<b>CT (±SD)</b>	<b>Difference</b>
<b>apoCIII</b>	VLDL FCR	1.3±0.7	1.8±0.5	0.59±0.38
	HDL FCR	1.3±0.7	1.9±0.3	0.56±0.55
	VLDL PR	7.4±6	4.9±2	-2.54±4.83
	HDL-PR	7.6±6	5±1	-2.68±5.34
<b>apoCII</b>	VLDL FCR	1.4±0.8	2.3±1	0.90±0.74
	HDL FCR	1.4±0.8	2.3±1	0.93±0.62
	VLDL PR	3.9±2	4.2±1	0.33±1.34
	HDL PR	4.0±2	4.4±1	0.41±1.31

**Supplemental Figure I. Apolipoprotein B100, VLDL TG and ApoCII/CIII Models**



**Figure Legend:** A1: ApoB 100 full model, this model accounts for all pathways considered to model our stable isotope data, A2. ApoB100 model used in the present study, B. VLDL-TG model, ApoC-II and apoC-III model.

## Supplemental Table II. Apolipoprotein C2, Apolipoprotein C3, Leucine, Phenylalanine and Glycerol Stable Isotope Enrichment Curves for Study Sib Pairs.



**Cont. Supplemental Table III. Apolipoprotein C2, Apolipoprotein C3, Leucine, Phenylalanine and Glycerol Stable Isotope Enrichment Curves for Study Sib Pairs.**

